Illiumina Inc., the American biotechnology company that designs and manufactures sequencing platforms and micro array scanners is undervalued, according to Wolfteam Ltd.'s revenue and profitability projections.
With revenue of 4.53 billion USD, growing at 39.73 %, net profit margin of 16.84 %, Illumina Inc's intrinsic value is 21 billion USD, compared with Illumina Inc's current market capitalization of 15.62 billion USD.
No comments:
Post a Comment